Clinical Trial Update: Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the immunogenicity and reactogenicity of an MPL-adjuvanted recombinant Hepatitis B vaccine versus Engerix-B in adult non-respo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• MPL-adjuvanted recombinant Hepatitis B vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED